Dama believes that Pharmaceutical Biotech (02269) has the ability to overcome turbulent times and achieve growth higher than market expectations.
The Zhitong Finance App learned that Morgan Stanley released a research report stating that it reiterated the “increase in holdings” rating of Pharmacology Biotech (02269). It is not surprising that the guidelines for this year and next two years have been adjusted. It is believed that the updated guidelines can narrow the gap between current business reality and previous extremely challenging guidelines, help adjust market expectations, ease market concerns about macroeconomic weakness, and provide a reasonable comparative basis for medium-term growth. The target price is HK$115.36.
The bank believes that Pharmaceutical Biotech is capable of overcoming turbulent times and achieving growth higher than market expectations. Furthermore, the bank still believes that Pharmaceutical Biotech is one of the companies most capable of driving development in the entire industry. Given its resilient and diversified CRDMO business model, the good operating record of the top management team, and the rapid growth of CMO orders, etc., it is believed that the company will outperform the market in the medium to long term.